Novartis Buys Fougera for $1.5B, gets Generic Metrogel

Written by on May 3, 2012 in in the news, Metrogel 1% with 0 Comments


News today that the giant pharmaceutical company Novartis International is buying Fougera Pharmaceuticals.

Fougera is known to rosacea sufferers through the availability of generic metronidazole 0.75%. Fougera will brings its specialty in generics to Sandoz, the generics division of Novartis.

Who is Novartis?

Novartis was previously the manufacturer of Elidel (Pimecrolimus cream 1%).

Novartis are also trialling BFH772 for the redness of rosacea (NCT01449591). BFH772 is also being trialled for Psoriasis (NCT00987870).

BFH772 appears to be a metrondizaole variant of some sort, perhaps a genuine competitor to Metrogel 1%.

Hopefully this further signals Novartis as a company willing to invest in treatments for rosacea.

Press Release

Novartis to Buy Fougera Pharmaceuticals for $1.5 Billion


Novartis International agreed on Wednesday to buy Fougera Pharmaceuticals, a maker of generic skin care medicine, for $1.525 billion in cash. The move would make the company the biggest manufacturer in the field.

It is the latest round of consolidation in the health care industry, a sector that has had a number of deals over recent weeks.

Under the terms of the deal, Fougera will be folded into Sandoz, the generics division of Novartis. The acquisition would give Novartis a leading position in generic treatments for ailments like acne, eczema and rosacea. The combined business will have an estimated $620 million in annual global sales, mostly in the United States.

Related Articles

Read more about: in the news, Metrogel 1%

About the Author

About the Author: David Pascoe started the Rosacea Support Group in October 1998. .

Follow Rosacea Support

Subscribe via RSS Feed

Leave your comment here


Subscribe to Rosacea News

Enter your email address to receive the latest news about rosacea in your inbox.